Daokun Yang
Xinxiang Medical University
6 Papers
8 Citations
Daokun Yang is an academic researcher from Xinxiang Medical University. The author has contributed to research in topics: Downregulation and upregulation & Biology. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Downregulation of miR‑141 deactivates hepatic stellate cells by targeting the PTEN/AKT/mTOR pathway.
TL;DR: It was observed that the downregulation of miR‑141 blocked the TGF‑β1‑induced activation of the AKT/mTOR pathway in HSCs and highlighted that miR‐141 may serve as a novel therapeutic target for liver fibrosis.
13
Analysis of drug-resistant gene detection of blaOXA-like genes from Acinetobacter baumannii.
TL;DR: It was found that isolated strains containing OxA-51 and OXA-23 were more likely to be resistant or have decreased sensitivity to carbapenems.
Association analysis between MDR1 gene polymorphisms and risk of hepatocellular carcinoma in Chinese population.
TL;DR: In this paper, the authors evaluated the association between MDR1 gene polymorphisms and hepatocellular carcinoma (HCC) risk using the created restriction site-polymerase chain reaction (CRS-PCR).
8
Discovery and mechanism of action of Novel Baicalein modified derivatives as potent antihepatitis agent.
Ji Ma,Teng-Fei Li,Xinwei Han,Huifeng Yuan,Haijun Liang,Wang Yanping,Xinwei Wang,Yuxiu Duan,Aihui Li,Huilian Song,Daokun Yang +10 more
TL;DR: Compound 4k showed excellent pharmacokinetic profile in experimental animal and thus, provide a novel class of potent anti-HBV agents, and shows significant effect on the HO-1 expression in HepG2.2.15 cells.
7
96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
Zhihong Liu,Qinglong Jin,Yuexin Zhang,Guozhong Gong,Guicheng Wu,Lvfeng Yao,Xiaofeng Wen,Zhiliang Gao,Yan Huang,Daokun Yang,Enqiang Chen,Qing Mao,Shide Lin,Jiali Shang,Huan-Yu Gong,Lihua Zhong,Hua-Fa Yin,Fengmei Wang,Qiong Wu,Chao Pan,Wenbin Qin Guorong Jia,Chuan Li,Changan Sun,Junqi Niu,Jinlin Hou +24 more
TL;DR: In this paper, the authors compared tenofovir amibufenamide (TMF) with TDF for chronic hepatitis B (CHBV) in 48 weeks of treatment.